AbbVie Drops After Earnings Land In Line, Bears Eye the Miss

Positioning in the lending market tells a comfortable story for longs. Short interest has fallen sharply, down nearly 14% over the past week and almost 18% over the past month, to just 0.89% of the free float. That is low enough that short-side pressure is not a meaningful factor in either direction. Borrow availability is essentially uncapped, with the lending pool showing no signs of tightness. Cost to borrow has ticked up 31% on the week to 0.51%, but that is still a negligible rate in absolute terms. Options positioning is similarly unremarkable: the put/call ratio of 0.84 is almost exactly at its 20-day average, a z-score of just -0.03, nowhere near the defensive extremes the 52-week high of 1.13 would represent. The ORTEX short score has eased to 30.9 from 32.1 a week ago, consistent with the retreat in short interest rather than any fresh bearish conviction.

The Street's posture is constructive but now slightly complicated by the print. The consensus mean target is $282.60, about 3% above Tuesday's close. Bullish targets from the recent upgrade cycle cluster well above that: Morgan Stanley is at $310, Scotiabank at $320, JP Morgan at $300. RBC reiterated its Outperform at $280 on October 13, the day of the selloff, while UBS maintains Neutral with a $275 target, essentially at-market. The forward earnings growth factor score ranks in the 81st percentile and the dividend score sits at the 98th percentile, which anchors the income argument. EPS surprise, however, ranks only in the 23rd percentile, consistent with a company that has a habit of landing in line rather than clearing the bar. The bull case leans on Skyrizi and Rinvoq momentum, pipeline depth in neuroscience and oncology, and Botox-driven aesthetics cash generation. Bears will point to the EPS miss, the IPR&D drag, and execution risk across a pipeline that includes the pending Apogee acquisition.

One alt-data signal worth carrying alongside the Street debate is the Medicaid utilisation data from the Centers for Medicare and Medicaid Services. For Q1 2026, Medicaid dollars reimbursed were down 10% on the same quarter a year earlier, and Medicaid prescription volumes fell 10% over the same period. None of AbbVie's alt-data datasets carry a measured lead status, so this cannot be characterised as a forward indicator for the revenue line. It is colour on the government-payer channel rather than a signal about the print. Retail attention, as measured by Wikipedia page views against AbbVie's own 90-day history, was running at a z-score of 2.9 as of October 1, suggesting elevated interest in the stock around the pre-earnings run-up period.

The post-earnings reaction is now the reference point. The previous two earnings prints produced a 1-day move of minus 4.8% after July results and plus 1.5% after the prior quarter, both followed by further weakness over five days. This print has so far produced a 2.4% one-day drop. Whether that stabilises or extends into the week ahead, with Skyrizi and Rinvoq prescription data and any pipeline newsflow acting as the next triggers, is what to watch.